Capricor Therapeutics (NASDAQ:CAPR) Shares Down 8.8% – Should You Sell?

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price dropped 8.8% during mid-day trading on Tuesday . The stock traded as low as $17.85 and last traded at $17.91. Approximately 1,103,225 shares traded hands during trading, a decline of 4% from the average daily volume of 1,147,935 shares. The stock had previously closed at $19.64.

Analysts Set New Price Targets

CAPR has been the topic of a number of recent research reports. Maxim Group increased their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Oppenheimer reiterated an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. Piper Sandler started coverage on Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a report on Thursday, November 14th. Finally, Cantor Fitzgerald upped their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Down 13.6 %

The business’s fifty day moving average is $18.31 and its two-hundred day moving average is $9.54. The stock has a market cap of $771.63 million, a price-to-earnings ratio of -16.90 and a beta of 3.98.

Insider Activity at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the stock in a transaction on Friday, September 20th. The stock was bought at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. The trade was a 65.21 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 12.00% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Several hedge funds have recently bought and sold shares of the company. Main Street Financial Solutions LLC lifted its stake in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Capricor Therapeutics during the 3rd quarter worth approximately $133,000. Bank of New York Mellon Corp raised its stake in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 9,040 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Capricor Therapeutics during the third quarter valued at approximately $161,000. Finally, Sassicaia Capital Advisers LLC bought a new stake in shares of Capricor Therapeutics in the 3rd quarter worth about $192,000. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.